Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
June 08, 2011
Medco Taps MolecularMD to Provide BCR-ABL Testing for TKI Inhibitors in CML Patients
Medco will offer MolecularMD's qRT-PCR BCR-ABL test to patients diagnosed with chronic myeloid leukemia in order to monitor their response to tyrosine kinase inhibitors such as Gleevec, Sprycel, and Tasigna.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Australia's Monoquant Developing PCR-Based DNA Assay to Monitor CML Patients
January 17, 2013 / PCR Insider - FDA Approves Ariad's Iclusig for Molecularly Defined, TKI-Resistant Leukemias
December 19, 2012 / Pharmacogenomics Reporter - FDA Approves Pfizer's Chronic Philadelphia Chromosome-Positive CML Drug Bosulif
September 5, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Cepheid Updates BCR-ABL Test; Medicare Covers Transgenomic Plavix Dx; Lungevity Awards
July 25, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter